AMARIN CORP PLC -ADR (AMRN) Fundamental Analysis & Valuation

NASDAQ:AMRN • US0231114044

Current stock price

14.29 USD
+0.33 (+2.36%)
At close:
14.29 USD
0 (0%)
After Hours:

This AMRN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

3

1. AMRN Profitability Analysis

1.1 Basic Checks

  • AMRN had positive earnings in the past year.
  • AMRN had a positive operating cash flow in the past year.
  • In the past 5 years AMRN reported 4 times negative net income.
  • In multiple years AMRN reported negative operating cash flow during the last 5 years.
AMRN Yearly Net Income VS EBIT VS OCF VS FCFAMRN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50M -100M -150M

1.2 Ratios

  • AMRN has a better Return On Assets (-5.78%) than 83.50% of its industry peers.
  • AMRN has a Return On Equity of -8.45%. This is amongst the best in the industry. AMRN outperforms 86.99% of its industry peers.
Industry RankSector Rank
ROA -5.78%
ROE -8.45%
ROIC N/A
ROA(3y)-8.29%
ROA(5y)-7.22%
ROE(3y)-12.02%
ROE(5y)-10.54%
ROIC(3y)N/A
ROIC(5y)N/A
AMRN Yearly ROA, ROE, ROICAMRN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200 400 600 800

1.3 Margins

  • Looking at the Gross Margin, with a value of 56.57%, AMRN is in the better half of the industry, outperforming 75.53% of the companies in the same industry.
  • In the last couple of years the Gross Margin of AMRN has declined.
  • AMRN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 56.57%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7.11%
GM growth 5Y-6.36%
AMRN Yearly Profit, Operating, Gross MarginsAMRN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. AMRN Health Analysis

2.1 Basic Checks

  • AMRN does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for AMRN has been increased compared to 1 year ago.
  • The number of shares outstanding for AMRN has been increased compared to 5 years ago.
  • There is no outstanding debt for AMRN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
AMRN Yearly Shares OutstandingAMRN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200K 400K 600K 800K 1M
AMRN Yearly Total Debt VS Total AssetsAMRN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.2 Solvency

  • Based on the Altman-Z score of -1.65, we must say that AMRN is in the distress zone and has some risk of bankruptcy.
  • AMRN's Altman-Z score of -1.65 is in line compared to the rest of the industry. AMRN outperforms 50.29% of its industry peers.
  • There is no outstanding debt for AMRN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z -1.65
ROIC/WACCN/A
WACC7.67%
AMRN Yearly LT Debt VS Equity VS FCFAMRN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 3.34 indicates that AMRN has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 3.34, AMRN is in line with its industry, outperforming 40.78% of the companies in the same industry.
  • A Quick Ratio of 2.33 indicates that AMRN has no problem at all paying its short term obligations.
  • The Quick ratio of AMRN (2.33) is worse than 71.46% of its industry peers.
Industry RankSector Rank
Current Ratio 3.34
Quick Ratio 2.33
AMRN Yearly Current Assets VS Current LiabilitesAMRN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. AMRN Growth Analysis

3.1 Past

  • AMRN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 125.78%, which is quite impressive.
  • The Revenue has decreased by -6.55% in the past year.
  • Measured over the past years, AMRN shows a very negative growth in Revenue. The Revenue has been decreasing by -19.04% on average per year.
EPS 1Y (TTM)125.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%88.16%
Revenue 1Y (TTM)-6.55%
Revenue growth 3Y-16.67%
Revenue growth 5Y-19.04%
Sales Q2Q%7.41%

3.2 Future

  • AMRN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 142.35% yearly.
  • Based on estimates for the next years, AMRN will show a very strong growth in Revenue. The Revenue will grow by 27.58% on average per year.
EPS Next Y3976%
EPS Next 2Y675.5%
EPS Next 3Y309.78%
EPS Next 5Y142.35%
Revenue Next Year-18.92%
Revenue Next 2Y-9.39%
Revenue Next 3Y-6.87%
Revenue Next 5Y27.58%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
AMRN Yearly Revenue VS EstimatesAMRN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 200M 400M 600M 800M
AMRN Yearly EPS VS EstimatesAMRN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -2 -4 -6 -8 -10

More info and screens

Find the best growth stocksShow best growing peers

6

4. AMRN Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 21.65 indicates a rather expensive valuation of AMRN.
  • Based on the Price/Earnings ratio, AMRN is valued cheaper than 92.62% of the companies in the same industry.
  • AMRN's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 26.54.
  • A Price/Forward Earnings ratio of 24.58 indicates a rather expensive valuation of AMRN.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of AMRN indicates a rather cheap valuation: AMRN is cheaper than 93.40% of the companies listed in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 21.68. AMRN is around the same levels.
Industry RankSector Rank
PE 21.65
Fwd PE 24.58
AMRN Price Earnings VS Forward Price EarningsAMRN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80 100

4.2 Price Multiples

  • Based on the Price/Free Cash Flow ratio, AMRN is valued cheaper than 92.62% of the companies in the same industry.
Industry RankSector Rank
P/FCF 44.55
EV/EBITDA N/A
AMRN Per share dataAMRN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15 20

4.3 Compensation for Growth

  • AMRN's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • AMRN's earnings are expected to grow with 309.78% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.01
PEG (5Y)N/A
EPS Next 2Y675.5%
EPS Next 3Y309.78%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. AMRN Dividend Analysis

5.1 Amount

  • No dividends for AMRN!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

AMRN Fundamentals: All Metrics, Ratios and Statistics

AMARIN CORP PLC -ADR

NASDAQ:AMRN (4/29/2026, 8:00:01 PM)

After market: 14.29 0 (0%)

14.29

+0.33 (+2.36%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Industry Strength33.78
Industry Growth78
Earnings (Last)04-29
Earnings (Next)N/A
Inst Owners22.33%
Inst Owner Change0.06%
Ins Owners0.86%
Ins Owner Change0.27%
Market Cap299.70M
Revenue(TTM)213.65M
Net Income(TTM)-38.80M
Analysts42.86
Price Target12.24 (-14.35%)
Short Float %41.13%
Short Ratio6.15
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)4.16%
Min Revenue beat(2)-4.67%
Max Revenue beat(2)12.99%
Revenue beat(4)2
Avg Revenue beat(4)5.53%
Min Revenue beat(4)-18.83%
Max Revenue beat(4)32.65%
Revenue beat(8)4
Avg Revenue beat(8)14.03%
Revenue beat(12)8
Avg Revenue beat(12)12.22%
Revenue beat(16)10
Avg Revenue beat(16)7.99%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)2000%
EPS NY rev (3m)3900%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.35%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.26%
Valuation
Industry RankSector Rank
PE 21.65
Fwd PE 24.58
P/S 1.4
P/FCF 44.55
P/OCF 44.55
P/B 0.65
P/tB 0.67
EV/EBITDA N/A
EPS(TTM)0.66
EY4.62%
EPS(NY)0.58
Fwd EY4.07%
FCF(TTM)0.32
FCFY2.24%
OCF(TTM)0.32
OCFY2.24%
SpS10.19
BVpS21.9
TBVpS21.26
PEG (NY)0.01
PEG (5Y)N/A
Graham Number18.0332 (26.19%)
Profitability
Industry RankSector Rank
ROA -5.78%
ROE -8.45%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 56.57%
FCFM 3.15%
ROA(3y)-8.29%
ROA(5y)-7.22%
ROE(3y)-12.02%
ROE(5y)-10.54%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7.11%
GM growth 5Y-6.36%
F-Score6
Asset Turnover0.32
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.34
Quick Ratio 2.33
Altman-Z -1.65
F-Score6
WACC7.67%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)125.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%88.16%
EPS Next Y3976%
EPS Next 2Y675.5%
EPS Next 3Y309.78%
EPS Next 5Y142.35%
Revenue 1Y (TTM)-6.55%
Revenue growth 3Y-16.67%
Revenue growth 5Y-19.04%
Sales Q2Q%7.41%
Revenue Next Year-18.92%
Revenue Next 2Y-9.39%
Revenue Next 3Y-6.87%
Revenue Next 5Y27.58%
EBIT growth 1Y75.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year61.49%
EBIT Next 3Y13.41%
EBIT Next 5YN/A
FCF growth 1Y121.69%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y121.69%
OCF growth 3YN/A
OCF growth 5YN/A

AMARIN CORP PLC -ADR / AMRN Fundamental Analysis FAQ

What is the fundamental rating for AMRN stock?

ChartMill assigns a fundamental rating of 4 / 10 to AMRN.


What is the valuation status for AMRN stock?

ChartMill assigns a valuation rating of 4 / 10 to AMARIN CORP PLC -ADR (AMRN). This can be considered as Fairly Valued.


What is the profitability of AMRN stock?

AMARIN CORP PLC -ADR (AMRN) has a profitability rating of 3 / 10.


What are the PE and PB ratios of AMARIN CORP PLC -ADR (AMRN) stock?

The Price/Earnings (PE) ratio for AMARIN CORP PLC -ADR (AMRN) is 21.65 and the Price/Book (PB) ratio is 0.65.